
Nvidia Gains on AI Deal as Biohaven Tumbles on Drug Trial
Nvidia's stock rose on a new AI deal, while Biohaven shares fell sharply after its depression drug trial missed its main goal. Sidus Space rallied on plans for a public offering.
#Nvidia#Biohaven#Sidus Space


